[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537189":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":22,"responsibleParty":51,"collaborators":7,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":7,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","OCT","Peripapillary angiography (OCT) at baseline and each year during 3 year",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Jean-Baptiste Ducloyer, M.D","CONTACT","02 40 08 34 01","jeanbatiste.ducloyer@chu-nantes.fr",{"name":20,"role":16,"phone":17,"phoneExt":7,"email":21},"Isabelle Orignac, M.D","isabelle.orignac@chu-nantes.fr",[23,40],{"facility":24,"status":25,"city":26,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"CHU Nantes","RECRUITING","Nantes","44000","France","FR",{"type":31,"coordinates":32},"Point",[33,34],-1.55336,47.21725,{"lat":34,"lon":33},[37],{"name":38,"role":16,"phone":7,"phoneExt":7,"email":39},"Ducloyer, MD; PhD","alexandra.poinas@chu-nantes.fr",{"facility":41,"status":42,"city":26,"state":26,"zip":43,"country":28,"countryCode":29,"cosmosGeoPoint":44,"geoPoint":46,"contacts":47},"Jean-Baptiste Ducloyer","NOT_YET_RECRUITING","44093",{"type":31,"coordinates":45},[33,34],{"lat":34,"lon":33},[48],{"name":49,"role":16,"phone":7,"phoneExt":7,"email":50},"Jean-Baptiste Ducloyer, MD","jeanbaptiste.ducloyer@chu-nantes.fr",{"type":52,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100537189","study-of-oct-peripapillary-angiography-in-patients-with-advanced-glaucoma-100537189",false,"NCT06274593","Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma","OGA","Inclusion Criteria:\n\n* Men and women aged 18 and over\n* Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital\n* mean visual field deficit (MD) \\>10dB\n\nExclusion Criteria:\n\n* Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR\u002FOBVR, OACR\u002FOBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...)\n* PPR (retinal PanPhotocoagulation), retinal cerclage\n* Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa)\n* AMD and other macular pathologies that can lead to central visual field deficits\n* Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract)\n* Loss of fixation point preventing visual field formation Pregnant or breast-feeding women\n* Protected adults under guardianship or curatorship\n* with unreliable visual fields (false positives and false negatives \\> 33%)\n* with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)","ALL","18 Years",{"count":63,"type":64},50,"ESTIMATED","OBSERVATIONAL","Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness.\n\nTo date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma.\n\nThe main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).",[68],"Glaucoma",[70,71,72],"glaucoma","OCTa","OCTrnfl","2026-06-23",{"date":75,"type":76},"2026-06-24","ACTUAL",{"date":78,"type":76},"2024-04-27",{"date":80,"type":64},"2027-09",{"name":5,"class":6},2]